Market Watch – Page 547 – Biotech Insider

All Posts in "Market Watch"

Gold reclaims $1,500 mark ahead of key central bank meetings

Gold steady ahead of ECB meeting Thursday and Fed meeting next week

by Editor — September 12, 2019 By Editor in Market Watch

Chesapeake Energy’s stock swings lower, but analysts are upbeat on debt-for-stock swap

Shares pull a sharp intraday reversal into negative territory as crude oil prices take a dive

by Editor — September 12, 2019 By Editor in Market Watch

U.S. stock futures rise after Trump delays tariff hikes against China until Oct. 15

President says move is ‘gesture of good will’

by Editor — September 12, 2019 By Editor in Market Watch

Dow closes higher for 6th straight session as tech shares power S&P 500

Dow back above 27,000 for first time since July; S&P500 above 3,000 for first time six weeks

by Editor — September 12, 2019 By Editor in Market Watch

Gold settles under $1,500, at lowest in 5 weeks

U.S. Treasury yields rise, dampening gold demand

by Editor — September 11, 2019 By Editor in Market Watch

Energy, financial stocks soar: Oversold bounce or the beginning of a break out?

Market laggards have turned to leaders

by Editor — September 11, 2019 By Editor in Market Watch

U.K. stocks inch higher as BlackRock advises investors to pounce on Brexit selloffs

Merger talks boost Gailliford Try, hurt Bovis Homes

by Editor — September 11, 2019 By Editor in Market Watch

Dow notches fifth straight gain as investors eye potential change in leadership

Apple rolls out new iPhones, iPad and Watch

by Editor — September 11, 2019 By Editor in Market Watch

Gold pulls back, suffer a 3-session skid

Yellow metal posts a loss Monday, extending last week’s decline

by Editor — September 10, 2019 By Editor in Market Watch

Uber to open new Chicago office, add about 2,000 jobs

Site will house company’s freight business, engineering hub

by Editor — September 10, 2019 By Editor in Market Watch

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Biotech Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.